Just Minutes To Go—See Why Intelligent Bio Solutions (NASDAQ: INBS) is Topping Our Watchlist Right Now

*Sponsored Market Crux Announces Its Next Potential Breakout Idea For Tuesday 3/25/2025. Intelligent Bio Solutions Inc. (NASDAQ: INBS) is Topping Our Early Watchlist This Morning. And Here’s Why… Scheduled To Present At 11:00 A.M. EST This Morning, Intelligent Bio Solutions Inc. (NASDAQ: INBS) Will Be Featured At The iAccess Alpha Best Ideas Spring Conference. With Fewer Than 7M Shares In The Float, Intelligent Bio Solutions Inc. (NASDAQ: INBS) Has The Potential To Witness Significant Swings If Demand Begins To Shift. Highlighted In Today’s Report From Ladenburg Thalmann, Intelligent Bio Solutions Inc. (NASDAQ: INBS) Was Assigned A $12 Target, Which Suggests Over 460% Upside Potential. After Moving Approximately 127% Over Two Months, Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is Starting To Attract New Eyes. Currently Triggering 12 Of 13 Bullish Signals, Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is Lighting Up Barchart’s Technical Indicators. Following Its FDA 510(k) Submission In December 2024, Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is Targeting A U.S. Launch Later This Year. See Why You Should Take A Look At Intelligent Bio Solutions Inc. (NASDAQ: INBS) Before the Bell Rings… March 25, 2025 Dear Reader, There’s just minutes to go before the bell rings. See why Intelligent Bio Solutions Inc. (NASDAQ: INBS) is topping our watchlist right now.  This one nearly slipped through the cracks—until we saw what’s happening today.  Tuesday morning, (today) March 25, 2025, at 11:00 a.m. EST, Intelligent Bio Solutions Inc. (NASDAQ: INBS) is scheduled to present at the iAccess Alpha Virtual Best Ideas Spring Conference—a platform known for surfacing under-followed names just before the spotlight finds them. It’s the kind of event that tends to mark the beginning of broader discovery—not the end of it. And that’s exactly what makes this story so exciting… No hype.  No mainstream buzz.  Just a little-known company gaining traction—still flying under most radars, despite a growing list of developments. With a market cap under $15M and a float of fewer than 7M shares, Intelligent Bio Solutions Inc. (NASDAQ: INBS) has the kind of structure that doesn’t need much to move—especially when attention begins to build. That attention may have kicked off earlier today… Yesterday, on March 24, 2025, Jeffrey S. Cohen, Director of Research and Managing Director of Equity Research in Healthcare & Medical Technologies at Ladenburg Thalmann—a firm with NYSE membership since 1879—published a report mentioning Intelligent Bio Solutions Inc. (NASDAQ: INBS) and assigning a $12 target—which suggests over 460% in upside potential from Monday’s $2.14 open. Even more interesting? That same “$2.14” opening number lines up with the 20-day moving average, a level many people watch for signs of strength—or weakness.  In this case, the trend appears to be leaning the right way. Over the last two months, Intelligent Bio Solutions Inc. (NASDAQ: INBS) has shown signs of momentum—moving approximately 127% between 12/19/2024 ($1.21) and 2/19/2025 ($2.75). Now, as of yesterday, (INBS) is trending at, near, or above every major moving average tracked by Barchart: -5-Day: 2.11 -20-Day: 2.14 -50-Day: 1.93 -100-Day: 1.73 -200-Day: 1.67 -Year-to-Date: 1.89 According to Barchart’s Technical Opinion tool, (INBS) is also triggering 12 out of 13 Bullish Signals across its Composite, Short-Term, Medium-Term, and Long-Term indicators. This isn’t just traction.  It’s the kind of alignment that often shows up before a larger shift in visibility. And with the company stepping into a market-focused spotlight tomorrow morning, there may still be time to get ahead of what comes next. Keep reading—and start your research on Intelligent Bio Solutions Inc. (NASDAQ: INBS) while it's still early. Most People Have No Idea What This Company Is Doing… When most people think of screening technology, they picture cold collection rooms, awkward procedures, and slow turnaround times.  Intelligent Bio Solutions Inc. (NASDAQ: INBS) is working to change that—with a system that doesn’t rely on urine, saliva, or needles, but instead uses fingerprint sweat to screen for commonly misused substances. The technology isn’t theoretical. It’s already in the field, with over 1,000 devices deployed across more than 400 active customer accounts—and it’s positioned to enter the U.S. market later this year. What makes the system different isn’t just the input method—it’s the simplicity, speed, and accuracy.  A fingerprint sample takes seconds to collect.  Results come back in under 10 minutes. And in a recently completed method comparison study submitted to the FDA, the system showed 94.1% accuracy and 100% specificity in screening for opiates using fingerprint sweat. At a time when employers are under increasing pressure to screen quickly, safely, and discreetly—without interrupting operations—this kind of system doesn’t just offer convenience. It could fundamentally change the expectations for workplace testing. Recent Developments March 25, 2025: Scheduled to Present at iAccess Alpha’s Best  Ideas Spring Conference Intelligent Bio Solutions Inc. (NASDAQ: INBS) is set to present at the iAccess Alpha Virtual Best Ideas Conference, a platform known for spotlighting under-the-radar names with meaningful upside potential.  The company’s 11:00 AM EST presentation on March 25 (today) is expected to showcase its non-invasive tech and upcoming U.S. rollout to a broader base of institutional and high-conviction individuals. Strengthening Its U.S. Patent Portfolio The company recently announced it expects a new U.S. patent grant tied to its core fingerprint screening system.  This expansion of its intellectual property footprint signals a broader, long-term commitment to building a defensible moat in the growing field of rapid, non-invasive workplace screening. Fiscal Q2 2025: Gross Margin Expansion and Strategic Growth For the quarter ending December 31, 2024, INBS reported a 32.6% year-over-year increase in gross profit and an expanded gross margin of 38.5%—up from 27.7% the year prior.  This growth was fueled in part by higher-margin cartridge sales and supported by 19 new customer accounts added during the quarter.  The company also reiterated its planned 2025 U.S. market entry, following the FDA 510(k) submission made in December. A Smaller Company with Real Revenue and Real Growth Despite a market cap under $15M, Intelligent Bio Solutions Inc. (NASDAQ: INBS) isn’t standing still. The company reported $3.11M in revenue for the fiscal year ended June 30, 2024—up 148% over the prior year.  Cartridge sales have steadily increased year over year, supporting a razor/razor-blade business model that encourages ongoing use once the reader is installed. Intelligent Bio Solutions Inc. (NASDAQ: INBS) submitted its FDA 510(k) application in December 2024. If cleared in the first half of 2025 as planned, the company intends to launch its fingerprint-based screening system in the U.S. in the second half of the year—initially for opiate detection, with a broader rollout to follow. The U.S. market could prove meaningful.  Substance misuse is estimated to cost the country over $400B annually, and the workplace is a key pressure point.  More than 70% of people misusing substances in the U.S. are employed, and dr-ug test positivity rates have risen steadily over the past five years. Why Fingerprint Screening? Intelligent Bio Solutions Inc. (NASDAQ: INBS)’s approach simplifies a process that’s long been considered intrusive and time-consuming.  The system requires no gender-specific supervision, produces no biohazard waste, and can be administered on-site without specialized training. It’s hygienic, fast, and discreet. Unlike traditional methods, which require samples to be sent to a lab—or involve waiting for an individual to be ready to provide a sample—the fingerprint system works on demand.  The collection process is touch-and-go, and the reader handles the rest. That simplicity translates to efficiency. Some of the company’s current customers estimate the system cuts the total cost of screening by half, not only by reducing direct testing costs but also by eliminating employee downtime and logistical hurdles. From Europe to the U.S.—With Data to Back It Up The technology isn’t new, and neither is the company’s customer base.  Intelligent Bio Solutions Inc. (NASDAQ: INBS) already serves accounts in the U.K. and other international markets, including P&O Ferries and industrial service groups.  These customers aren’t participating in a pilot—they’re running real-world programs, at scale, with tangible operational benefits. The company’s recent clinical work supports its expansion goals. In a pharmacokinetic (PK) study comparing codeine levels in fingerprint sweat to levels in blood and saliva, results tracked closely—further validating the fingerprint method as a reliable indicator of recent use. And in a separate method comparison study involving 135 subjects, the fingerprint system’s results matched closely with those from high-precision LC-MS/MS lab analysis—a gold-standard method in screening. Looking Ahead Intelligent Bio Solutions Inc. (NASDAQ: INBS) may be small today, but its combination of working technology, revenue traction, and upcoming U.S. launch puts it in a different category than early-stage peers still in development mode. With a low float (under 7M shares), a business model designed for repeat usage, and a product addressing a growing workplace demand, the company may be at a point where fundamentals start catching up with the story. Fingerprinting has always been used to identify people.  Intelligent Bio Solutions Inc. (NASDAQ: INBS) is now showing it can also be used to detect what they’ve been exposed to—with surprising speed, accuracy, and ease. Whether that ends up reshaping how companies approach screening remains to be seen. But the groundwork is already in motion—and for those watching closely, Intelligent Bio Solutions Inc. (NASDAQ: INBS) isn’t hard to spot. 7 Reasons Why Intelligent Bio Solutions Inc. (NASDAQ: INBS) is Topping Our Watchlist This Morning… 1. Today’s Spotlight Moment: Intelligent Bio Solutions Inc. (NASDAQ: INBS) is scheduled to present at the iAccess Alpha Best Ideas Spring Conference on March 25 at 11:00 a.m. EST—a visibility event known for surfacing emerging names before the crowd catches on. 2. Ultra-Small Float: With fewer than 7M shares available, Intelligent Bio Solutions Inc. (NASDAQ: INBS) has the kind of low-float structure that has historically magnified attention when momentum begins to build. 3. Analyst Coverage: Ladenburg Thalmann’s March 24 report put Intelligent Bio Solutions Inc. (NASDAQ: INBS) on radar with a target that suggests over 460% upside potential. 4. Momentum That’s Hard to Ignore: Intelligent Bio Solutions Inc. (NASDAQ: INBS) moved approximately 127% in just two months—from $1.21 in December to $2.75 in February—while most weren’t watching. 5. Technical Signals: Barchart shows Intelligent Bio Solutions Inc. (NASDAQ: INBS) triggering 12 out of 13 Bullish Signals across Composite, Short-Term, Medium-Term, and Long-Term indicators. 6. Adoption Is Already Underway: Over 400 customers are using Intelligent Bio Solutions Inc. (NASDAQ: INBS)’s system in real-world environments—with 1,000+ readers already deployed. 7. Positioned for U.S. Expansion: After submitting its FDA 510(k) in December 2024, Intelligent Bio Solutions Inc. (NASDAQ: INBS) is aiming to enter the U.S. market in 2025 with its first planned system rollout. Take a Look at Intelligent Bio Solutions Inc. (NASDAQ: INBS)  While It's Still Early… Let’s be honest—most names presenting tomorrow won’t come with a razor-thin float, a real product already in the field, and an analyst target that suggests over 460% upside potential from today’s open.  But Intelligent Bio Solutions Inc. (NASDAQ: INBS) checks every one of those boxes—and then some. It’s got momentum. It’s triggering signals. And it’s walking into a high-visibility event tomorrow with a story that’s still largely untold. We have all eyes on (INBS) this morning. Consider taking a look at (INBS) before the bell rings.  There’s less than 15 minutes to go. Also—keep an eye out for my next update—could be coming at any moment. Sincerely, Gary Silver Managing Editor, MarketCrux MarketCrux.com (“MarketCrux” or “MC” ) is owned by Headline Media LLC, a multi member limited liability company. Data is provided from third-party sources and MarketCrux is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MC brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in.vest.ment advice, are not in.vest.ment advisors, and any profiles we mention are not suitable for all in.vest.ors. The owners of Headline Media LLC own and operate marketcrux . com (“MC”). From time to time, MC will publicly disseminate information about a company via website, email, SMS and other points of media. Please see important disclosure information here: marketcrux.com/disclaimer/  *Pursuant to an agreement between Headline Media LLC and TD Media LLC, Headline Media LLC has been hired for a period beginning on 03/24/2025 and ending on 03/25/2025 to publicly disseminate information about (INBS:US) via digital communications. Under this agreement, Headline Media LLC has been paid five thousand USD (“Funds”). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the Funds directly or indirectly from the Issuer and does not own stock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Headline Media LLC, TD Media LLC and their member own shares of (INBS:US). Please see important disclosure information here: https://marketcrux.com/disclosure/inbs/#details

Headline Media | 7901 4th Street N Suite 300 | St. Petersburg, FL 33702 US Unsubscribe | Update Profile | Constant Contact Data Notice